Matsuyama Takatoshi, Uetake Hiroyuki, Aoyagi Haruhiko, Kobayashi Hirotoshi, Ishikawa Toshiaki, Iida Satoru, Higuchi Tetsuro, Yasuno Masamichi, Enomoto Masayuki, Sugihara Kenichi
Dept. of Surgical Oncology, Tokyo Medical and Dental University Graduate School.
Gan To Kagaku Ryoho. 2008 Nov;35(12):2147-9.
We present a case of hand-foot syndrome (HFS) induced by bolus 5-fluorouracil (5-FU) therapy. A 54-year-old man received bolus 5-FU for adjuvant treatment of rectal cancer. After second cycle, he presented to the clinic with a rash on the both palms accompanied by symptoms of pain, erythema, swelling, and desquamation consistent with grade 2 HFS. HFS appears more frequently with 5-FU delivered by continuous infusion or with the 5-FU oral derivative capecitabine than with bolus 5-FU therapy. HFS is a leading cause of treatment interruption which may impact on the efficacy of the treatment regimen. This possibility must be considered when patient is receiving a bolus 5-FU treatment, and effective and appropriate patient education is an essential part of management to prevent progression to a more severe grade of toxicity by early detection of HFS.
